Trials / Completed
CompletedNCT01432353
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma. Cohorts of patients will receive multiple ascending doses of intravenous DFRF4539A every 3 weeks or weekly. Patients exhibiting acceptable safety and evidence of clinical benefit may receive DFRF4539A for up to 17 cycles. Anticipated time on study treatment is 1 year or until disease progression or unacceptable toxicity occurs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DFRF4539A | multiple ascending doses |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2011-09-13
- Last updated
- 2016-11-02
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01432353. Inclusion in this directory is not an endorsement.